Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Neurizon Therapeutics LimitedTelephone
61.3.9692.7222
Address
Level 4 96-100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.08 - 0.54
Trade Value (12mth)
AU$60,103.00
1 week
-5%
1 month
-2.56%
YTD
72.73%
1 year
143.59%
All time high
4.74
EPS 3 yr Growth
481.00%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-68.90%
ROIC
-118.60%
Interest Coverage
N/A
Quick Ratio
12.40
Shares on Issue (Fully Dilluted)
445m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.02
Date | Announcements |
---|---|
01 November 24 |
Application for quotation of securities - NUZ
×
Application for quotation of securities - NUZ |
01 November 24 |
Application for quotation of securities - NUZ
×
Application for quotation of securities - NUZ |
01 November 24 |
Application for quotation of securities - NUZ
×
Application for quotation of securities - NUZ |
01 November 24 |
Application for quotation of securities - NUZ
×
Application for quotation of securities - NUZ |
01 November 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
31 October 24 |
Appendix 4C & Quarterly Update
×
Appendix 4C & Quarterly Update |
25 October 24 |
Neurizon Presents Phase 1 MEND Study Data at NEALS Meeting
×
Neurizon Presents Phase 1 MEND Study Data at NEALS Meeting |
15 October 24 |
PharmAust changes name to Neurizon Therapeutics
×
PharmAust changes name to Neurizon Therapeutics |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.